Single-Nucleotide Polymorphism Array Technique Generating Valuable Risk-Stratification Information for Patients With Myelodysplastic Syndromes
Background: Chromosomal abnormalities play an important role in the diagnosis and prognosis of patients with myelodysplastic syndromes (MDSs). The single-nucleotide polymorphism array (SNP-A) technique has gained popularity due to its improved resolution compared to that of metaphase cytogenetic (MC...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.00962/full |
| _version_ | 1818539581132242944 |
|---|---|
| author | Xia Xiao Xiaoyuan He Qing Li Wei Zhang Haibo Zhu Weihong Yang Yuming Li Li Geng Hui Liu Lijuan Li Huaquan Wang Rong Fu Mingfeng Zhao Mingfeng Zhao Zhong Chen Zonghong Shao |
| author_facet | Xia Xiao Xiaoyuan He Qing Li Wei Zhang Haibo Zhu Weihong Yang Yuming Li Li Geng Hui Liu Lijuan Li Huaquan Wang Rong Fu Mingfeng Zhao Mingfeng Zhao Zhong Chen Zonghong Shao |
| author_sort | Xia Xiao |
| collection | DOAJ |
| description | Background: Chromosomal abnormalities play an important role in the diagnosis and prognosis of patients with myelodysplastic syndromes (MDSs). The single-nucleotide polymorphism array (SNP-A) technique has gained popularity due to its improved resolution compared to that of metaphase cytogenetic (MC) analysis.Methods: A total of 376 individuals were recruited from two medical centers in China, including 350 patients and 26 healthy individuals. Among these patients, 200 were diagnosed with de novo MDS, 25 with myeloproliferative neoplasm (MPN), 63 with primary acute myeloid leukemia (AML), and 62 with idiopathic cytopenia of undetermined significance (ICUS). We evaluated the significance of abnormal chromosomes detected by SNP-A in the diagnosis and prognosis of MDS-related disorders.Results: (1) When certain chromosomal abnormalities could not be detected by conventional MC methods, these abnormalities could be detected more efficiently by the SNP-A method. With SNP-A, the detection rates of submicroscopic or cryptic aberrations in the MDS, MPN, and AML patients with normal MC findings were 32.8, 30.8, and 30%, respectively. (2) The chromosomal abnormalities detected by SNP-A had a very important value for the prognosis of patients with MDSs, especially in the low-risk group. The survival of patients with abnormal chromosomes detected by SNP-A was significantly lower than that of patients with no detected chromosomal abnormalities; this difference was observed in overall survival (OS) (P = 0.001) and progression-free survival (PFS) [24 months vs. not reach (NR); P = 0.008]. The patients with multiple chromosomal abnormalities detected by SNP-A had an inferior prognosis, and SNP-A abnormalities (≥3 per patient) were found to be an independent predictor of poor prognosis in patients with MDSs [hazard ratio (HR) = 2.40, P = 0.002]. (3) Patients with ICUS may progress to myeloid malignancies, but most patients often maintain a stable ICUS status for many years without progression. An ICUS patient found to have an MDS-related karyotype would be rediagnosed with MDS. SNP-A can efficiently detect chromosomal abnormalities, which would be important for assessing the evolution of ICUS. In our study, 17 ICUS patients with SNP-A-detected abnormalities developed typical MDSs.Conclusions: SNP-A can help evaluate the prognosis of patients with MDSs and better assess the risk of disease progression for patients with ICUS. |
| first_indexed | 2024-12-11T21:43:57Z |
| format | Article |
| id | doaj.art-6db78893688f4111b4f0aea54e7d81ae |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-11T21:43:57Z |
| publishDate | 2020-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-6db78893688f4111b4f0aea54e7d81ae2022-12-22T00:49:44ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-07-011010.3389/fonc.2020.00962506844Single-Nucleotide Polymorphism Array Technique Generating Valuable Risk-Stratification Information for Patients With Myelodysplastic SyndromesXia Xiao0Xiaoyuan He1Qing Li2Wei Zhang3Haibo Zhu4Weihong Yang5Yuming Li6Li Geng7Hui Liu8Lijuan Li9Huaquan Wang10Rong Fu11Mingfeng Zhao12Mingfeng Zhao13Zhong Chen14Zonghong Shao15Department of Hematology, Tianjin First Central Hospital, Tianjin, ChinaDepartment of Clinical Medicine, Nankai University School of Medicine, Tianjin, ChinaDepartment of Hematology, Tianjin First Central Hospital, Tianjin, ChinaDepartment of Hematology, Tianjin Medical University General Hospital, Tianjin, ChinaDepartment of Hematology, Tianjin First Central Hospital, Tianjin, ChinaWuhan Kindstar Diagnostics Co./Kindstar Global Gene (Beijing) Technology, Inc., Wuhan, ChinaDepartment of Hematology, Tianjin First Central Hospital, Tianjin, ChinaDepartment of Hematology, Tianjin First Central Hospital, Tianjin, ChinaDepartment of Hematology, Tianjin Medical University General Hospital, Tianjin, ChinaDepartment of Hematology, Tianjin Medical University General Hospital, Tianjin, ChinaDepartment of Hematology, Tianjin Medical University General Hospital, Tianjin, ChinaDepartment of Hematology, Tianjin Medical University General Hospital, Tianjin, ChinaDepartment of Hematology, Tianjin First Central Hospital, Tianjin, ChinaDepartment of Clinical Medicine, Nankai University School of Medicine, Tianjin, ChinaWuhan Kindstar Diagnostics Co./Kindstar Global Gene (Beijing) Technology, Inc., Wuhan, ChinaDepartment of Hematology, Tianjin Medical University General Hospital, Tianjin, ChinaBackground: Chromosomal abnormalities play an important role in the diagnosis and prognosis of patients with myelodysplastic syndromes (MDSs). The single-nucleotide polymorphism array (SNP-A) technique has gained popularity due to its improved resolution compared to that of metaphase cytogenetic (MC) analysis.Methods: A total of 376 individuals were recruited from two medical centers in China, including 350 patients and 26 healthy individuals. Among these patients, 200 were diagnosed with de novo MDS, 25 with myeloproliferative neoplasm (MPN), 63 with primary acute myeloid leukemia (AML), and 62 with idiopathic cytopenia of undetermined significance (ICUS). We evaluated the significance of abnormal chromosomes detected by SNP-A in the diagnosis and prognosis of MDS-related disorders.Results: (1) When certain chromosomal abnormalities could not be detected by conventional MC methods, these abnormalities could be detected more efficiently by the SNP-A method. With SNP-A, the detection rates of submicroscopic or cryptic aberrations in the MDS, MPN, and AML patients with normal MC findings were 32.8, 30.8, and 30%, respectively. (2) The chromosomal abnormalities detected by SNP-A had a very important value for the prognosis of patients with MDSs, especially in the low-risk group. The survival of patients with abnormal chromosomes detected by SNP-A was significantly lower than that of patients with no detected chromosomal abnormalities; this difference was observed in overall survival (OS) (P = 0.001) and progression-free survival (PFS) [24 months vs. not reach (NR); P = 0.008]. The patients with multiple chromosomal abnormalities detected by SNP-A had an inferior prognosis, and SNP-A abnormalities (≥3 per patient) were found to be an independent predictor of poor prognosis in patients with MDSs [hazard ratio (HR) = 2.40, P = 0.002]. (3) Patients with ICUS may progress to myeloid malignancies, but most patients often maintain a stable ICUS status for many years without progression. An ICUS patient found to have an MDS-related karyotype would be rediagnosed with MDS. SNP-A can efficiently detect chromosomal abnormalities, which would be important for assessing the evolution of ICUS. In our study, 17 ICUS patients with SNP-A-detected abnormalities developed typical MDSs.Conclusions: SNP-A can help evaluate the prognosis of patients with MDSs and better assess the risk of disease progression for patients with ICUS.https://www.frontiersin.org/article/10.3389/fonc.2020.00962/fullmyelodysplastic syndrome (MDS)idiopathic cytopenia of undetermined significance (ICUS)single-nucleotide polymorphism (SNP)chromosome aberrationsprognosis |
| spellingShingle | Xia Xiao Xiaoyuan He Qing Li Wei Zhang Haibo Zhu Weihong Yang Yuming Li Li Geng Hui Liu Lijuan Li Huaquan Wang Rong Fu Mingfeng Zhao Mingfeng Zhao Zhong Chen Zonghong Shao Single-Nucleotide Polymorphism Array Technique Generating Valuable Risk-Stratification Information for Patients With Myelodysplastic Syndromes Frontiers in Oncology myelodysplastic syndrome (MDS) idiopathic cytopenia of undetermined significance (ICUS) single-nucleotide polymorphism (SNP) chromosome aberrations prognosis |
| title | Single-Nucleotide Polymorphism Array Technique Generating Valuable Risk-Stratification Information for Patients With Myelodysplastic Syndromes |
| title_full | Single-Nucleotide Polymorphism Array Technique Generating Valuable Risk-Stratification Information for Patients With Myelodysplastic Syndromes |
| title_fullStr | Single-Nucleotide Polymorphism Array Technique Generating Valuable Risk-Stratification Information for Patients With Myelodysplastic Syndromes |
| title_full_unstemmed | Single-Nucleotide Polymorphism Array Technique Generating Valuable Risk-Stratification Information for Patients With Myelodysplastic Syndromes |
| title_short | Single-Nucleotide Polymorphism Array Technique Generating Valuable Risk-Stratification Information for Patients With Myelodysplastic Syndromes |
| title_sort | single nucleotide polymorphism array technique generating valuable risk stratification information for patients with myelodysplastic syndromes |
| topic | myelodysplastic syndrome (MDS) idiopathic cytopenia of undetermined significance (ICUS) single-nucleotide polymorphism (SNP) chromosome aberrations prognosis |
| url | https://www.frontiersin.org/article/10.3389/fonc.2020.00962/full |
| work_keys_str_mv | AT xiaxiao singlenucleotidepolymorphismarraytechniquegeneratingvaluableriskstratificationinformationforpatientswithmyelodysplasticsyndromes AT xiaoyuanhe singlenucleotidepolymorphismarraytechniquegeneratingvaluableriskstratificationinformationforpatientswithmyelodysplasticsyndromes AT qingli singlenucleotidepolymorphismarraytechniquegeneratingvaluableriskstratificationinformationforpatientswithmyelodysplasticsyndromes AT weizhang singlenucleotidepolymorphismarraytechniquegeneratingvaluableriskstratificationinformationforpatientswithmyelodysplasticsyndromes AT haibozhu singlenucleotidepolymorphismarraytechniquegeneratingvaluableriskstratificationinformationforpatientswithmyelodysplasticsyndromes AT weihongyang singlenucleotidepolymorphismarraytechniquegeneratingvaluableriskstratificationinformationforpatientswithmyelodysplasticsyndromes AT yumingli singlenucleotidepolymorphismarraytechniquegeneratingvaluableriskstratificationinformationforpatientswithmyelodysplasticsyndromes AT ligeng singlenucleotidepolymorphismarraytechniquegeneratingvaluableriskstratificationinformationforpatientswithmyelodysplasticsyndromes AT huiliu singlenucleotidepolymorphismarraytechniquegeneratingvaluableriskstratificationinformationforpatientswithmyelodysplasticsyndromes AT lijuanli singlenucleotidepolymorphismarraytechniquegeneratingvaluableriskstratificationinformationforpatientswithmyelodysplasticsyndromes AT huaquanwang singlenucleotidepolymorphismarraytechniquegeneratingvaluableriskstratificationinformationforpatientswithmyelodysplasticsyndromes AT rongfu singlenucleotidepolymorphismarraytechniquegeneratingvaluableriskstratificationinformationforpatientswithmyelodysplasticsyndromes AT mingfengzhao singlenucleotidepolymorphismarraytechniquegeneratingvaluableriskstratificationinformationforpatientswithmyelodysplasticsyndromes AT mingfengzhao singlenucleotidepolymorphismarraytechniquegeneratingvaluableriskstratificationinformationforpatientswithmyelodysplasticsyndromes AT zhongchen singlenucleotidepolymorphismarraytechniquegeneratingvaluableriskstratificationinformationforpatientswithmyelodysplasticsyndromes AT zonghongshao singlenucleotidepolymorphismarraytechniquegeneratingvaluableriskstratificationinformationforpatientswithmyelodysplasticsyndromes |